Royalty Pharma (RPRX) Net Income Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) Net Income Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 79.26% |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | Royalty Pharma | 25.79 Bn | 25.19 Bn | - | -2.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.75% |
| Dec 31, 2025 | 37.21% |
| Sep 30, 2025 | 26.31% |
| Jun 30, 2025 | -43.08% |
| Mar 31, 2025 | 50.25% |
| Dec 31, 2024 | 84.00% |
| Sep 30, 2024 | 53.77% |
| Jun 30, 2024 | -37.77% |
| Mar 31, 2024 | -26.55% |
| Dec 31, 2023 | 25.09% |
| Sep 30, 2023 | -41.96% |
| Jun 30, 2023 | -16.43% |
| Mar 31, 2023 | 67.11% |
| Dec 31, 2022 | -34.29% |
| Sep 30, 2022 | -20.58% |
| Jun 30, 2022 | 40.10% |